Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

Схожие документы

• Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up
  по: Martin Dreyling, et al.
  Опубликовано: (2022-05-01)
• Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
  по: Wang, Michael L., et al.
  Опубликовано: (2013)
• Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies
  по: Rule, Simon, et al.
  Опубликовано: (2017)
• Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
  по: Peterson, Derek, et al.
  Опубликовано: (2014)
• Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
  по: Maruyama, Dai, et al.
  Опубликовано: (2016)